miR-137 inhibits renal cell carcinoma growth in vitro and in vivo
Affiliations: Health Examination Center, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China
- Published online on: May 24, 2016 https://doi.org/10.3892/ol.2016.4616
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
MicroRNA (miR)-137 has been reported to be underexpressed and involved in various cell processes and to have antitumor effects in a range of tumors, but so far not in renal cell carcinoma (RCC). The aim of the present study was to investigate the clinical significance and role of miR‑137 in RCC. The expression levels of miR‑137 were determined by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) in 50 cases of paired RCC tissues and adjacent normal tissues, and in RCC cell lines. The role of miR‑137 in the growth and survival of RCC cells was assessed with several in vitro approaches and in nude mice models. The results of the RT‑qPCR showed that the miR‑137 expression was downregulated in the RCC tissues and cell lines. The in vitro assay showed that ectopic expression of miR‑137 robustly impaired RCC cell proliferation, migratory and invasive properties, and increased the induction of cell apoptosis properties. The in vivo assay demonstrated that enforced miR‑137 suppressed tumor growth in xenograft nude mice models. In addition, miR‑137 was indicated to inhibit the activation of phosphoinositide 3 kinase/protein kinase B signal pathway, which contributes to the inhibition of RCC growth. These findings indicate that miR-137 functions as tumor suppressor in RCC, suggesting that miR-137 may be a potential therapeutic target for RCC.